申请人:Mitsubishi Pharma Corporation
公开号:US07105567B2
公开(公告)日:2006-09-12
The present invention relates to a urea derivative of the formula (1)
wherein each symbol is as described in the specification, a pharmaceutically acceptable salt thereof and pharmaceutical use thereof. The compound of the present invention has a C5a receptor antagonistic action and is useful as an agent for the prophylaxis or treatment of diseases or syndromes due to inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis, pancreatitis and the like) due to activation of leukocytes caused by ischemia, trauma, burn, surgical invasion and the like]. In addition, it is useful as an agent for the prophylaxis or treatment of infectious diseases caused by bacteria or virus that invades via a C5a receptor.
本发明涉及一种尿素衍生物(1)的公式,其中每个符号如规范所述,其药学上可接受的盐及其药用。本发明的化合物具有C5a受体拮抗作用,可用作预防或治疗由C5a引起的炎症所致的疾病或综合征的药剂[例如,自身免疫性疾病,如风湿病,系统性红斑狼疮等,败血症,成人呼吸窘迫综合征,慢性阻塞性肺疾病,过敏性疾病,如哮喘等,动脉粥样硬化,心脏梗塞,脑梗塞,牛皮癣,阿尔茨海默病和严重器官损伤(例如肺炎,肾炎,肝炎,胰腺炎等),由缺血,创伤,烧伤,手术侵入等引起的白细胞激活所致]。此外,它还可用作预防或治疗由通过C5a受体侵入的细菌或病毒引起的感染性疾病的药剂。